Additionally, it is necessary to systematize analytical studies comparing different aspects of PV, ET and PMF given that, despite their similarities, there are genetic and clinical markers that differentiate this subgroup, among which is frequency of mutations such as JAK2, MPL and CALR. Additionally, given the large number of reports on these frequencies, it is necessary to obtain a global measure that summarizes the large number of publications and allows the real prevalence of genetic markers in the subgroup of BCR-ABL-negative MPN to be known. This evidence concerns the gene MPL and myeloproliferative disorder.